AUS
NZ
UK
CA
USA
IND
Highlights:
- Island Pharmaceuticals completes enrolment for the phase 2b segment of the PROTECT trial.
- The trial examines ISLA-101’s role in reducing dengue virus symptoms.
- Comprehensive trial data expected in the final quarter of FY25
Island Pharmaceuticals Ltd (ASX:ILA), a company in the health and biotechnology sector, has reached a significant milestone with the completion of subject enrolment for the phase 2b segment of its phase 2a/b PROTECT clinical trial. This trial focuses on the antiviral drug ISLA-101, designed to address the global health challenge posed by dengue fever.
Dual-Cohort Study Design for Comprehensive Evaluation
The PROTECT trial is organized into two distinct cohorts to assess ISLA-101’s effectiveness in different scenarios. The phase 2a cohort focuses on the drug’s ability to act as a preventive measure. Participants in this group received ISLA-101 prior to exposure to an attenuated strain of the dengue virus. This approach aims to evaluate how effectively the drug can reduce or prevent infection when administered proactively.
Meanwhile, the phase 2b cohort concentrates on therapeutic outcomes. This segment, now fully enrolled, assesses ISLA-101’s role in reducing viral load and easing symptoms in individuals already infected with dengue. The combination of both preventive and therapeutic evaluations aims to provide extensive insights into ISLA-101’s overall utility in addressing dengue infections.
Progression Driven by Safety and Efficacy Data
The transition from phase 2a to phase 2b was based on the favorable safety and antiviral activity data reviewed by the Safety Review Committee (SRC). The positive review led to regulatory clearance from the US Food and Drug Administration, enabling the immediate progression of the trial.
Enrolment for the phase 2b cohort has been successfully completed, with all participants now part of the therapeutic study. This achievement reflects Island Pharmaceuticals' progress in meeting clinical trial objectives and timelines, offering valuable data on ISLA-101’s performance in managing dengue-related symptoms.
Anticipated Data Releases in 2025
Dr. David Foster, managing director and CEO of Island Pharmaceuticals, acknowledged the importance of this milestone, especially considering the growing prevalence of dengue fever worldwide. The increasing demand for specific treatments highlights the relevance of this study in the global health landscape.
Initial high-level data from the phase 2b trial is expected around April 2025. Comprehensive unblinded data from both the phase 2a and 2b cohorts are projected for release in the final quarter of FY25. This timeline marks a critical period for gathering insights into the role of ISLA-101 in dengue fever management, providing detailed clinical outcomes from both preventive and therapeutic perspectives.
